NCT04512521View on ClinicalTrials.gov

Functional Lung MRI for Early Treatment Response Assessment for Patients With Eosinophilic Asthma

UnknownOBSERVATIONAL

Enrollment

40

Participants

Timeline

Start Date

May 4, 2020

Primary Completion Date

February 28, 2025

Study Completion Date

August 31, 2025

Conditions

Asthma; Eosinophilic

Interventions

DRUG

Mepolizumab

Mepolizumab therapy

Trial Locations (1)

30625

RECRUITING

Hannover Medical School, Hanover

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Hannover Medical School

OTHER

NCT04512521 - Functional Lung MRI for Early Treatment Response Assessment for Patients With Eosinophilic Asthma | Biotech Hunter | Biotech Hunter